Graves disease (GD)-associated hyperthyroidism is an autoimmune disorder characterized by the presence of autoantibodies that stimulate the thyroid-stimulating hormone receptor (TSHR), leading to ...

Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.